<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Inappropriate implantable cardioverter-defibrillator (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e>) therapies can lead to significant adverse events and increased mortality </plain></SENT>
<SENT sid="1" pm="."><plain>These therapies are often the result of <z:hpo ids='HP_0004755'>supraventricular tachycardias</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SVTs</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>The objective of this study was to evaluate the incidence of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SVT</z:e> leading to inappropriate shocks in a large cohort of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICDs</z:e> and assess the efficacy of radiofrequency ablation (RFA) in decreasing these therapies </plain></SENT>
<SENT sid="3" pm="."><plain>Patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICDs</z:e> and recurrent <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SVTs</z:e> were identified </plain></SENT>
<SENT sid="4" pm="."><plain>A cohort of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapies subsequently underwent electrophysiologic study and RFA </plain></SENT>
<SENT sid="5" pm="."><plain>Eighty-four patients (13%) were found to have <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SVT</z:e> leading to 122 inappropriate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> shocks and 130 episodes of antitachycardia pacing therapies </plain></SENT>
<SENT sid="6" pm="."><plain>Median time to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SVT</z:e> <z:hpo ids='HP_0003674'>onset</z:hpo> after <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> implantation was 269 days </plain></SENT>
<SENT sid="7" pm="."><plain>Electrophysiologic studies were performed in 30 patients </plain></SENT>
<SENT sid="8" pm="."><plain>Successful RFA was performed for atrial <z:hpo ids='HP_0001649'>tachycardia</z:hpo>, <z:hpo ids='HP_0004749'>atrial flutter</z:hpo>, or atrioventricular nodal reentrant <z:hpo ids='HP_0001649'>tachycardia</z:hpo> in 22 patients </plain></SENT>
<SENT sid="9" pm="."><plain>Ninety-five percent of patients who underwent successful <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SVT</z:e> ablation had no further inappropriate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapies compared to 63% of patients in whom ablation was not performed during a mean follow-up of 20.7 Â± 11.9 months </plain></SENT>
<SENT sid="10" pm="."><plain>In conclusion, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SVT</z:e> is responsible for a significant number of inappropriate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapies </plain></SENT>
<SENT sid="11" pm="."><plain>RFA is an effective strategy to substantially decrease subsequent inappropriate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapies </plain></SENT>
</text></document>